![]() |
|
|
Vol. 31, Issue 5, 620-630, May 2003
Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (H.W., S.R.F., D.G., S.L.J., E.L.L.); and Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina (T.S., M.N.)
| |
Abstract |
|---|
|
|
|---|
Although the glucocorticoid receptor (GR) facilitates the xenobiotic-induced expression of CYP2B in rodents, its role in the regulation of human CYP2B6 is unclear. In this report, the role of human GR in the regulation of CYP2B6 was evaluated using primary human hepatocytes and transfection assays with Huh7 cells. CYP2B6 expression was not induced in primary hepatocytes treated with dexamethasone (DEX) concentrations (0.01-1 µM) known to activate GR. In contrast, treatment with 0.1 µM DEX enhanced CYP2B6 induction by different pregnane X receptor (PXR) activators, including rifampin, phenytoin, clotrimazole, and phenobarbital. In Huh7 cells, cotransfection of human (h)GR and hPXR with CYP2B6-phenobarbital-responsive enhancer module (PBREM) reporter constructs revealed that all hPXR ligands induce CYP2B6 reporter gene activity, and this ligand-dependent activation is greatly enhanced by activated hGR. CYP2B6 reporter gene expression was not induced in the presence of hPXR ligands when hGR alone was cotransfected with CYP2B6 reporter construct. In hGR and human constitutive androstane receptor (hCAR) cotransfection assays, activated hGR increased the constitutive activation of PBREM reporter constructs by hCAR in the absence of inducers. In the presence of activated hGR and known inducers of CYP2B6, only PB treatment caused a further 2-fold activation of hCAR compared with control. These studies show that hGR is involved synergistically in the xenobiotic-responsive regulation of human CYP2B6 by hPXR and hCAR. Moreover, the results suggest that the GR-enhanced expression of CYP2B6 is mediated through an indirect mechanism that does not require increased expression of nuclear receptor.
| |
Introduction |
|---|
|
|
|---|
Cytochrome P450s
(P450s)1 constitute a superfamily of heme-containing
monooxygenases that catalyze the biotransformation of a broad range of
endogenous and xenobiotic chemicals (Nelson, 1999
; Parkinson, 2001
).
CYP2B6 has been thought to play a minor role in human drug metabolism
and xenobiotic biotransformation; therefore, it has received little
attention in pharmacology and toxicology (Mimura et al., 1993
; Shimada
et al., 1994
). This concept has been challenged by recent studies that
estimate the average relative abundance of CYP2B6 to be at least 5% of
the total hepatic P450 content and by the fact that up to 25% of all
pharmaceutical drugs are metabolized to some extent by CYP2B6 (Code et
al., 1997
; Ekins, 1999
; Stresser, 1999
; Faucette et al., 2000
; Hanna et
al., 2000
; Hesse et al., 2000
). Also of importance, CYP2B6 is highly inducible and significant interindividual differences in hepatic CYP2B6
expression exist (Xie and Evans, 2001
). However, the molecular determinants of human CYP2B6 expression and regulation by xenobiotics remain unclear.
Transcriptional activation of CYP genes by xenobiotics is
mediated by the interaction of ligand-nuclear receptor complexes with
enhancer sequences that lie upstream of CYP gene promoters (Kliewer et al., 1999
; Waxman, 1999
). Recently, pregnane X receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3) have
been proposed as xenobiotic-responsive transcription factors that
regulate multiple drug-metabolizing enzymes (Bertilsson et al., 1998
;
Xie et al., 2000
; Geick et al., 2001
). Extensive studies by Negishi and
coworkers have revealed that CAR regulates the induction of rodent
CYP2B gene expression by phenobarbital (PB) and PB-like compounds
(Honkakoski et al., 1998
; Kawamoto et al., 1999
). In studies performed
in CAR knockout mice, total ablation of Cyp2b10 induction by PB and
1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is observed (Wei et
al., 2000
; Ueda et al., 2002
). Although human CAR shares many common
characteristics with its rodent counterparts, it also displays unique
ligand specificities, as well as other distinct properties (Kawamoto et
al., 2000
).
PXR is the closest relative of CAR within the orphan nuclear receptor
superfamily. Although they are originally recognized as the regulator
of CYP3A and CYP2B, respectively, significant overlap is observed
between CYP2B and CYP3A induction by the same inducers (Xie et al.,
2000
; Goodwin et al., 2001
). The mechanism underlying the shared
induction of CYP2B and CYP3A currently is unknown, but may result from
the cross talk of CAR and PXR by recognition of common response
elements (Xie et al., 2000
).
In contrast to hCAR and hPXR, the role of GR in the CYP2B6 basal and
xenobiotic-induced expression in human liver has not been extensively
explored. GR is activated upon binding of glucocorticoids in various
tissues and can regulate gene transcription by activation as well as
repression (Beato et al., 1995
). Submicromolar concentrations of
dexamethasone (DEX) known to activate hGR do not induce CYP2B6 expression at the mRNA level (Pascussi et al., 2000b
). Using a GR
knockout animal model, Schuetz et al. (2000)
demonstrated that GR-deficient mice challenged with DEX failed to induce CYP2B proteins, whereas CYP2B was readily induced in wild-type mice by DEX (Schuetz et
al., 2000
). Furthermore, the basal hepatic expression of CYP2B was
decreased in mice lacking GR, whereas the constitutive expression of
liver CYP3A was not affected (Schuetz et al., 2000
). Given these
findings, it is clear that GR plays an important role in both the basal
and inducible expression of CYP2B by glucocorticoids in mice. However,
the role of GR in the overall regulation of human CYP2B6 gene
expression remains to be determined.
In the current study, we report the roles of GR and hPXR in the regulation of CYP2B6 expression in primary cultures of human hepatocytes. Different hPXR activators such as rifampicin (RIF), PB, phenytoin (PHY), and clotrimazole (CLZ) were chosen to evaluate the relationship of hPXR activation and CYP2B6 induction. In addition, the presence or absence of DEX cotreatment was examined for its effect on PXR-mediated regulation of CYP2B6. Furthermore, CYP2B6 and CYP3A4 mRNA and protein expression patterns, and PXR mRNA expression levels were compared in human primary hepatocytes treated with DEX (0.001-1 µM). Cotransfection of GR and hPXR or hCAR with hPBREM or NR1 reporter vectors in Huh7 cells was performed to examine whether hPXR ligands activate CYP2B6 PBREM reporter gene expression, and whether it is enhanced by the activation of exogenous GR. The results from these studies suggest that hPXR may play an important role in the regulation of CYP2B6, and this effect is greatly facilitated by GR activation. Moreover, GR alone does not directly regulate CYP2B6 expression in human primary hepatocytes, but rather seems to work synergistically with hPXR and hCAR to regulate xenobiotic-responsive CYP2B6 expression.
| |
Materials and Methods |
|---|
|
|
|---|
Materials and Reagents. DMEM and modified Chee's medium (MCM) were purchased from Invitrogen (Carlsbad, CA). Matrigel and ITS+ were obtained from Collaborative Research (Bedford, MA). Collagenase IV was from Sigma-Aldrich (St. Louis, MO) and petri dishes (60 mm, LUX, Permanox) were from Nalge Nunc International (Naperville, IL). DEX, PB, RIF, PHY, CLZ, bupropion hydrochloride (BUP), NADP+, glucose 6-phosphate, and glucose-6-phosphate dehydrogenase were purchased from Sigma-Aldrich. Effectene transfection reagent was obtained from QIAGEN (Valencia, CA). Dual-luciferase reporter assay system was from Promega (Madison, WI). All other reagents were purchased from commercial suppliers and were either American Chemical Society or molecular biology grade.
Plasmids.
The expression vector for human PXR was generously provided by Dr.
Bingfang Yan (University of Rhode Island, Kingston, RI). Human GR
expression vector was a kind gift from Dr. John Cidlowski (National
Institute of Environmental Health Sciences, Research Triangle Park,
NC). Human CAR expression vector and the reporter construct with the
human PBREM cloned in front of the tk promoter termed hPBREM-tk-LUC
were as described by Sueyoshi et al. (1999)
. A 5-repeat human NR1
(5'-gatcACTGTACTTTCCTGACCTTGgatc-3') sequence was synthesized and
cloned into the KpnI/XhoI site of pGL3-promoter vector, resulting in a (NR1)5-LUC plasmid.
Culture and Treatment of Primary Human Hepatocytes.
Hepatocytes were isolated from human liver specimens by a modification
of the two-step collagenase digestion method as described by Hamilton
et al. (2001)
. Liver tissues were obtained by qualified medical staff,
with donor consent and the approval of the University of North Carolina
Hospitals Ethics Committee. All tissues were obtained from donors
undergoing liver resections for metastatic tumors. Only hepatocytes
exhibiting normal morphological features and viabilities greater than
80% were plated into collagen-coated 60-mm Permanox culture dishes
(Nalge Nunc International) at the density of 4 × 106 cells/dish in 3 ml of serum-free MCM
containing 6.25 µg/ml insulin, 6.25 µg/ml transferrin, and 6.25 ng/ml selenium (ITS+). After 2 to 4 h of attachment at 37°C in a
humidified incubator with an air/CO2 ratio of
95:5, cultures were overlaid with ice-cold medium containing 0.25 mg/ml
Matrigel. Medium containing the appropriate concentration of DEX as
outlined under Results was changed on a daily basis
thereafter. Cultures were incubated for an additional 36 to 48 h
before initiating experiments with inducers.
Measurement of Bupropion and Testosterone Hydroxylase Activities.
The activity of CYP2B6 was determined by measuring the rate of
hydroxylation of BUP (Faucette et al., 2000
). Briefly, microsomes isolated from cultured human hepatocytes (0.1 mg) were incubated at
37°C in 0.25-ml incubation mixtures containing potassium phosphate buffer (50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM), NADP+ (1 mM), glucose 6-phosphate (5 mM),
glucose-6-phosphate dehydrogenase (1unit/ml), and BUP (500 µM).
Reactions were started by the addition of the NADPH-generating system
and terminated 30 min later by addition of ice-cold acetonitrile (125 µl). On completion of the reaction, reaction mixtures were vortexed
and centrifuged at 2000g for 5 min. The amount of
hydroxy-BUP in the supernatant fraction was determined by
C18 reverse-phase high-performance liquid
chromatography preceded by a BDS-Hypersil C18
guard cartridge using UV detection set at 210 nm. Elution was achieved
at 1 ml/min using a binary gradient of solvent A (0.025M potassium
phosphate, 1 ml/l triethylamine, pH 7.0 in 95:5 water/acetonitrile) and
solvent B (acetonitrile). CYP3A4 activity was determined by measuring
the production of 6
-hydroxytestosterone as described by Pearce et
al. (1996)
.
SDS-Polyacrylamide Gel Electrophoresis and Immunoblotting Analysis. Microsomal protein (10-30 µg) was separated by SDS-polyacrylamide gel electrophoresis (9%), and electrophoretically transferred to polyvinylidene difluoride blotting membrane. Membranes were probed with specific antibodies against CYP2B6 or CYP3A4 peptide (Chemicon International), and developed with an enhanced chemiluminescence detection system (Amersham Biosciences Inc., Piscataway, NJ). The relative amounts of CYP2B6 and CYP3A4 protein were estimated from densitometry analysis of the blot after scanning.
Transfection of Hepatoblastoma Cells. A human liver-derived cell line, Huh7, was cultured in DMEM/F-12 supplemented with 10% charcoal stripped fetal bovine serum (HyClone Laboratories, Logan, UT) and antibiotics. Briefly, 5 × 104 cells/well were plated into 24-well plates and transfected 24 h later with Effectene transfection reagent (QIAGEN). Transfection mixtures consisted of 100 ng of hPBREM-LUC or (NR1)5-LUC reporter constructs, 50 ng of hPXR or hCAR with and without 50 ng of hGR cotransfection, and 10 ng of pRL-tk vector as internal control. Cells were maintained for a further 24 h in the presence of different combinations of compounds in DMEM/F-12. Luciferase activity was measured using the dual-Luciferase reporter assay system (Promega). Promoter activities were determined from three independent transfections and calculated from firefly luciferase activities normalized against Renilla luciferase activities of the internal control pRL-tk vector.
Real-Time PCR.
Total RNA was isolated from human hepatocytes using RNease Midi kit
(QIAGEN). cDNAs were prepared from total RNA using SuperScript II
reverse transcriptase (Invitrogen). The primers and the TaqMan probes
were designed using Primer Express software (Applied Biosystems, Foster
City, CA) from the human mRNA sequence as follows: CYP2B6 1299 to 1366 bp, forward primer 5'-AAGCGGATTTGTCTTGGTGAA-3', reverse primer
5'-TGGAGGATGGTGGTGAAGAAG-3', probe 6FAM-CATCGCCCGTGCGGAATTGTTC-TAMRA; CYP3A4 673 to 796 bp, forward primer 5'-TCAATAACAGTCTTTCCATTCCTCAT-3', reverse primer 5'-CTTCGAGGCGACTTTCTTTCA-3', probe
6FAM-TTTCCAAGAGAAGTTAC-MGBNFQ; and human PXR 1497 to 1556 bp, forward
primer 5'-CGAGCTCCGCAGCATCA-3', reverse primer
5'-TGTATGTCCTGGATGCGCA-3', probe 6FAM-TGCTCAGCACACCCAGCGGCT-TAMRA. Intron-exon junctions were considered for the primers and probes designed to avoid potential genomic DNA interference, and CYP3A4 primers and probe were designed to exclude nonselective amplification of CYP3A5 and CYP3A7. For an internal control,
-actin mRNA was measured using Predeveloped TaqMan assay reagents for human
-actin (Applied Biosystems). The mRNA quantitation of CYP2B6, CYP3A4, or hPXR
was normalized to
-actin mRNA and expressed as fold induction and
compared with a control mRNA value of 1. Amplification and detection
were performed using the ABI PRISM 7700 sequence detector system
(Applied Biosystems).
| |
Results |
|---|
|
|
|---|
Various PXR Ligands Induce CYP2B6 Expression and Activity in
Primary Human Hepatocyte Cultures.
Microsomes isolated from a single preparation of human hepatocytes
(HLN-126) treated with a panel of known PXR ligands for 72 h were
analyzed for CYP2B6 protein content and activity by immunoblotting and
BUP hydroxylation, respectively. CYP2B6 protein content was induced
12-fold by 10 µM RIF, 19-fold by 1 mM PB, 13-fold by 50 µM PHY, and
7-fold by 10 µM CLZ (Fig. 1A). Similar induction patterns were observed in two different human liver preparations (HLN-129: 16-fold by 10 µM RIF, 11-fold by 100 µM PB,
6-fold by 10 µM CLZ; HLN-131: 15-fold by 10 µM RIF, 27-fold by 1 mM
PB, 19-fold by 50 µM PHY, and 9-fold by 10 µM CLZ). PB (1 mM)
showed the greatest extent of CYP2B6 induction, which may be mediated
by the activation of both CAR and PXR. However, potent induction of
CYP2B6 was also observed with two potent PXR activators RIF and CLZ.
Because CLZ is a PXR activator but a CAR deactivator (Moore et al.,
2000
), induction of CYP2B6 by RIF and CLZ suggests that PXR also may
play an important role in the regulation of CYP2B6.
|
Effects of Submicromolar Levels of DEX on CYP2B6, CYP3A4, and PXR
Expression.
Initial studies using human primary hepatocyte cultures (HLN-109)
demonstrated that different concentrations of DEX from 0.001 to 1 µM
did not induce CYP2B6 protein and mRNA expression (Figs. 2A and 3A). It has been shown that this
range of DEX (hereafter referred to as
low DEX concentrations) activates GR but
not PXR or CAR (Pascussi et al., 2000a
; Falkner et al., 2001
). In
parallel experiments, CYP3A4 expression was also analyzed under the
same low concentrations of DEX. In contrast with CYP2B6, both CYP3A4 mRNA and protein expression were induced in a dose-dependent manner by
DEX concentrations between 0.01 and 1 µM (Figs. 2B and 3B). These
notably different profiles for CYP2B6 and CYP3A4 induction by low
concentrations of DEX suggest that the CYP2B6 promoter region lacks an
effective GRE. Notably, under our experimental conditions, no
significant induction of PXR mRNA was observed upon treatment with low
concentrations of DEX (Fig. 3C). Similar results were obtained in
hepatocytes isolated from two separate donors (data not shown).
|
|
Enhancement of CYP2B6 Induction by PXR Ligands in Presence of DEX. To determine whether DEX cotreatment enhances CYP2B6 induction by PXR ligands, hepatocyte cultures were maintained in medium with or without 0.1 µM DEX before and during treatment with different PXR ligands. The results showed that DEX enhanced the CYP2B6 protein content and activity of hepatocytes treated with all compounds tested in this study (Fig. 4, A and B). On the other hand, real-time PCR results indicated that under the treatment conditions used in these studies, DEX significantly increased CYP2B6 mRNA levels in hepatocytes treated with RIF (10 µM), CLZ (10 µM), and PB (100 µM), but not in those treated with PB (1 mM) or PHY (50 µM) (Fig. 4C). Overall, these results indicate that although activated GR does not directly induce CYP2B6 expression itself, it augments the expression of CYP2B6 by most, but not all, prototypical inducers.
|
Cotransfection of GR with PXR Synergistically Activates CYP2B6
Reporter Constructs by DEX and PXR Ligands.
A 51-bp PBREM located
1.7 kilobases upstream of the 5'-flanking
region of the CYP2B6 gene contains two imperfect DR4 elements (NR1 and
NR2), which were identified as the most important response elements
mediating transcriptional activation of CYP2B6 by CAR (Sueyoshi et al.,
1999
). Recent studies have indicated that in vitro translated
PXR-RXR
heterodimers also could bind to the NR1 and NR2 within the
PBREM region (Xie et al., 2000
; Goodwin et al., 2001
). To test the
hypothesis that activated GR could enhance PXR regulation of CYP2B6
gene expression by facilitating PXR activation of CYP2B6 reporter
constructs, experiments were carried out in a liver-derived cell line
(Huh7) transiently transfected with various plasmids.
|
|
Effects of Cotransfected GR on Human CAR Activation by Different
Compounds.
In the absence of exogenous ligand, cell lines transfected with human
CAR exhibited high basal reporter activity compared with those without
nuclear receptor transfection, which is in agreement with the
observations of Sueyoshi et al. (1999)
. Further treatment with RIF, PB,
or CLZ did not significantly increase PBREM reporter activity (Fig.
7A). In addition, the presence of 0.1 µM DEX did not change the CAR-mediated CYP2B6 reporter gene expression pattern under these cotransfection conditions. In contrast, Huh7 cells cotransfected with GR showed markedly enhanced hCAR-mediated reporter activity in the presence of 0.1 µM DEX (Fig. 7B). Under these conditions, treatment with 1 mM PB caused an increase (2-fold) in
reporter activity over that of controls, whereas RIF and CLZ elicited
no increase in reporter expression.
|
| |
Discussion |
|---|
|
|
|---|
Transcriptional regulation of CYP2B gene expression in rodents has
been well characterized, and it has been established that CAR
predominantly mediates CYP2B1 and CYP2b10 expression in rats and mice,
respectively (Honkakoski et al., 1998
; Wei et al., 2000
). However,
notable species-specific differences in CYP2B induction and CAR
activation have hampered the extrapolation of these data to humans.
Although human CAR exhibits some common characteristics with its rodent
counterparts, such as its ability to be translocated into the nucleus
upon PB treatment, and the ability of binding to the conserved PBREM
sequence, notable differences exist between rodent and human CAR
(Pascussi et al., 2000b
). For example, androstenol, progesterone,
androgens, and calcium/calmodulin-dependent kinase inhibitors,
which are known mCAR inhibitors, do not inhibit activation of
hCAR (Zelko and Negishi, 2000
). To date, no effective human CAR
activator has been reported in transfection assays using cell lines.
This is in part due to the constitutive activity of CAR in cell-based
transfection assays.
Recently, a number of studies have suggested that the human CYP2B6 gene
might be cross-regulated by PXR because it can recognize sequences in
the known PBREM located upstream of the CYP2B6 gene (Xie et al., 2000
;
Goodwin et al., 2001
). In this study, we report that a number of known
PXR ligands can effectively induce CYP2B6 expression and activity in
primary human hepatocyte cultures and that CYP2B6 induction by these
ligands is augmented by submicromolar concentrations of DEX. These
results indicate that optimal PXR activation of human PBREM occurs
through a GR-dependent mechanism.
DEX is an important synthetic glucocorticoid and has been reported to
play a biphasic role in CYP3A4 and glutathione S-transferase A2 gene expression (Falkner et al., 2001
; Pascussi et al., 2001
). Previous studies have indicated that submicromolar concentrations of
DEX (
0.1 µM) enhance PB-induced CYP2B6 expression in primary human
hepatocytes (Pascussi et al., 2000b
). In the current study, a
physiologically relevant concentration of DEX (0.1 µM) was shown to
effectively enhance CYP2B6 induction in human hepatocyte cultures treated with various human PXR ligands. Inasmuch as DEX is neither an
activator of hCAR nor hPXR at this concentration, an indirect effect of
the nuclear receptor GR must be involved in this process.
Using low concentrations of DEX (0.001-1 µM), which have been
shown to activate GR but not PXR (Kliewer et al., 1998
; Pascussi et
al., 2000a
), we found that the constitutive levels of both CYP2B6
protein content and activity were not affected, whereas a
dose-dependent induction of CYP3A4 protein content and activity was
observed. Recently, El-Sankary et al. (2002)
reported that mutation of an HNF-3/CCAAT-enhancer
protein binding site in the
CYP3A4 proximal promoter could disrupt DEX-mediated CYP3A4 reporter
activity, but did not affect induction by the PXR ligand rifampicin.
These results indicated that GR could regulate CYP3A4 expression
through direct activation of sequences in the CYP3A4 proximal promoter
region that is independent of PXR. Moreover, using GR knockout mice,
Schuetz et al. (2000)
reported that GR is essential for both the basal
and DEX-inducible expression of Cyp2b10, suggesting a direct
involvement of GR in mouse CYP2B gene expression (Schuetz et
al., 2000
). Overall, these results indicate that different mechanisms
are involved in the regulation of the basal expression of CYP2B6 and
CYP3A4 by physiological concentrations of glucocorticoids and that
human and mouse GR exert distinct effects on CYP2B gene regulation.
PBREM is highly conserved among the CYP2B gene subfamily members and is
believed to be the most important CYP2B6 regulatory unit (Sueyoshi et
al., 1999
). Several lines of evidence indicate that PXR cross-regulates
CYP2B expression by recognizing this PB response element. In
vitro-translated PXR has been shown to effectively bind to the NR1 and
NR2 within PBREM located upstream of the CYP2B6 gene using
electrophoretic mobility shift assay (Goodwin et al., 2001
). In
contrast, Huh7 cell-based transfection assays demonstrated that
exposure to PXR ligands in the absence of GR cotransfection and DEX
cotreatment results only in modest PBREM activation. On the other hand,
DEX-activated human GR can greatly enhance PXR-mediated activation of
the CYP2B6 reporter gene by various CYP3A4 inducers and PXR ligands.
Currently, the exact mechanism of this DEX effect on CYP2B6 expression
is not clear. Because low levels of DEX are required for the
maintenance of hepatocyte cultures (Macdonald et al., 2001
), one
explanation might be that DEX enhances the expression of other genes,
including coactivators, such as steroid receptor coactivators or cAMP
response element-binding protein, by a nonspecific mechanism
that maintains the overall transcriptional and synthetic capacity of
the cells (Laishes and Williams, 1976
). Although DEX is involved in
multiple gene expression patterns and physiological functions, our
results in cell-based transfection assays have revealed that
DEX-mediated GR activation is essential for the enhanced effect on PXR
activation of the CYP2B6 protein and gene expression. Neither DEX nor
exogenous GR alone could increase PXR-mediated CYP2B6 reporter gene
expression. Moreover, these studies have demonstrated that activated GR
can also enhance hCAR-mediated constitutive expression of CYP2B6
reporter gene in Huh7 cells. Under this condition, only 1 mM PB
treatment caused a significant increase in CYP2B6 reporter gene
expression compared with that of controls, whereas RIF and CLZ had no
effect on hCAR activation.
Another possible explanation for these synergistic effects is that 0.1 µM DEX increases the expression of PXR and CAR through a potential
GRE located in the promoter region of these two nuclear receptors
(Pascussi et al., 2000b
; Maurel, 2002
). However, results from
this study indicate that additional mechanisms may also be involved in
this process. Under the current experimental conditions, 0.1 µM DEX
did not significantly increase the expression of human PXR mRNA
expression levels. Thus, enhancement of CYP2B6 induction by PXR ligands
in the presence of 0.1 µM DEX cannot be fully explained by DEX
induction of PXR expression. Moreover, in the Huh7 cell transfection
system, the endogenous PXR levels are extremely low and the PXR
expression vector lacks the PXR promoter region, which might
potentially contain a GRE. This suggests that an increase in PXR
expression levels alone cannot account for the observed enhancement of
cotransfecting hGR in this system.
An alternative mechanism is that activated GR translocates from
the cytoplasm into the nucleus where PXR, RXR, and activated CAR are
located, and functions as a coactivator to facilitate binding of
nuclear receptor heterodimers to the response elements of target genes.
Although several studies have indicated that both NR1 and NR2 are
important for the optimal activation of the CYP2B gene, quantitatively
the NR1 motif plays a much more important role in CYP2B regulation
(Honkakoski et al., 1998
; Goodwin et al., 2001
). In this report, we
generated a pGL3-(NR1)5-LUC reporter construct
and found similar activation profiles as was observed for the full
PRBEM in the PXR/GR cotransfection assay. These results indicate that
PXR-mediated CYP2B6 expression occurs predominantly through PXR
activation of the NR1 of PBREM. Although several GREs have been
identified in the regulatory region of rat and mouse CYP2B genes, some
of which can be activated by GR (Jaiswal et al., 1990
), no functional
consensus GRE has been identified in the human CYP2B6 gene thus far.
Accordingly, human GR may function as a cofactor to facilitate PXR and
CAR binding to their target genes. It remains to be determined whether
a potential GRE might exist in the regulatory regions of the PXR or CAR
genes, and whether GR is involved directly in the regulation of other
nuclear receptors.
In summary, our data suggest that PXR ligands and CYP3A4 inducers can effectively induce human CYP2B6 expression through PXR-mediated PBREM activation. More importantly, human GR is integrally involved in the regulation of CYP2B6 by both PXR and CAR. These studies also suggest an additional mechanism for the GR-enhanced induction of CYP2B6 by prototypical inducers, whereby activated GR acts as a cofactor to facilitate the binding of PXR and CAR to CYP2B6 response elements. As such, physiological levels of glucocorticoids could differentially influence CYP2B6 induction by various nuclear receptor ligands through a GR-mediated pathway.
| |
Acknowledgments |
|---|
We thank Drs. Bingfang Yan and John Cidlowski for providing nuclear receptor expression vectors and Stephan Ferguson for helpful discussion in preparing this manuscript.
| |
Footnotes |
|---|
Received October 23, 2002; accepted February 10, 2003.
Address correspondence to: Dr. Edward L. LeCluyse, School of Pharmacy, Kerr Hall, CB 7360, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599. E-mail: ed_lecluyse{at}unc.edu
| |
Abbreviations |
|---|
Abbreviations used are: P450, cytochrome P450; PXR, pregnane X receptor; CAR, constitutive androstane receptor; PB, phenobarbital; GR, glucocorticoid receptor; MCM, modified Chee's medium; DEX, dexamethasone; RIF, rifamipicin; PHY, phenytoin; CLZ, clotrimazole; BUP, bupropion; PBREM, phenobarbital-responsive enhancer module; DMSO, dimethyl sulfoxide; HLN, human liver number; PCR, polymerase chain reaction; bp, base pair(s); GRE, glucocorticoids responsive element.
| |
References |
|---|
|
|
|---|
expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators.
Mol Pharmacol
58:
361-372This article has been cited by other articles:
![]() |
V. S. Narang, C. Fraga, N. Kumar, J. Shen, S. Throm, C. F. Stewart, and C. M. Waters Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier Am J Physiol Cell Physiol, August 1, 2008; 295(2): C440 - C450. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma Neuro-oncol, April 1, 2008; 10(2): 190 - 198. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Urquhart, R. G. Tirona, and R. B. Kim Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wang, A. J. Mendy, G. Dai, H.-R. Luo, L. He, and Y.-J. Y. Wan Retinoids Activate the RXR/SXR-Mediated Pathway and Induce the Endogenous CYP3A4 Activity in Huh7 Human Hepatoma Cells Toxicol. Sci., July 1, 2006; 92(1): 51 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, et al. EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 1004 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hempel, H. Wang, E. L. LeCluyse, M. E. McManus, and M. Negishi The Human Sulfotransferase SULT1A1 Gene Is Regulated in a Synergistic Manner by Sp1 and GA Binding Protein Mol. Pharmacol., December 1, 2004; 66(6): 1690 - 1701. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, S. Faucette, R. Moore, T. Sueyoshi, M. Negishi, and E. LeCluyse Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin J. Biol. Chem., July 9, 2004; 279(28): 29295 - 29301. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Jackson, S. S. Ferguson, R. Moore, M. Negishi, and J. A. Goldstein The Constitutive Active/Androstane Receptor Regulates Phenytoin Induction of Cyp2c29 Mol. Pharmacol., June 1, 2004; 65(6): 1397 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Faucette, H. Wang, G. A. Hamilton, S. L. Jolley, D. Gilbert, C. Lindley, B. Yan, M. Negishi, and E. L. LeCluyse REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS Drug Metab. Dispos., March 1, 2004; 32(3): 348 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Handschin and U. A. Meyer Induction of Drug Metabolism: The Role of Nuclear Receptors Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||